Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.
Commentary|Articles|October 13, 2026
FAQ: SYD-101 heads to FDA advisory committee: What clinicians should know
Author(s)Kassi Filkins
Fact checked by: Nimesh Patel, MD
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to review new drug application (NDA) 219694 for SYD-101 (atropine sulfate ophthalmic solution 0.01%; Sydnexis), proposed for slowing myopia progression in children aged 3 years or older.1
Related to this article
A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.
Eyes on September 2026: ESCRS insights, gene therapy wins, and the push to treat myopia as a disease
September was one of the busiest months of the year in eye care—From ESCRS to Eyecon
Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.
David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.
Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight.
Timothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.
Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.
Advertisement
Advertisement